肠道菌群失调在慢性肝病发病中的作用研究进展

doi:10.3969/j.issn.1672-5069.2014.01.034

摘要/Abstract

摘要： 肠道菌群是肠道屏障的重要组成部分,在健康状态下肠道菌群与机体之间处于平衡状态。当某种原因引起机体内外环境发生变化破坏了该平衡状态时,即出现肠道菌群失调。肠道菌群失调可以促进各种慢性肝脏疾病的发生与发展。应用益生菌治疗能够改善肠道菌群失调,从而为治疗慢性肝脏疾病带来更好的疗效。

关键词: 肝硬化, 非酒精性脂肪性肝病, 酒精性肝病, 肠道菌群失调

Abstract: Intestinal flora is an important part of the intestinal barrier. Under healthy condition,a normal balance of intestinal flora is maintained, however, under pathological circumstances a number of factors can change the balance and result in dysbacteriosis. In turn dysbacteriosis promotes the progress and exacerbation of chronic liver diseases. Administration of probiotics can improve the balance of intestinal flora and help the recovery of chronic liver disease.

Key words: Cirrhosis, Non-alcoholic fatty liver disease, Alcoholic liver disease, Dysbacteriosis

赵欣综述, 赵彩彦审校. 肠道菌群失调在慢性肝病发病中的作用研究进展[J]. 实用肝脏病杂志, 2014, 17(1): 106-109.

Zhao Xin, Zhao Caiyan. Progress in dysbacteriosis in chronic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 106-109.

参考文献

[1] 贾辅忠. 肝病与肠道微生态环境. 中国实用内科杂志,2006, 26（13）：971-974.
[2] 姜秀菊. 肠道菌群失调与多脏器功能衰竭. 中国微生态学杂志, 2008,20（4）：424.
[3] Woo PC,Fung AM,Lau SK,et al. Identification by 16S rRNA gene sequencing of Lactobacillus salivarius bacteremic cholecystitis. J Clin Microbiol,2002,40（1）：265-257.
[4] 沈镭,陆伦根. 肠道微生态与肝硬化. 肝脏,2006,11（4）：278-280.
[5] Bliss SK,Bliss SP,Beiting DP,et al. IL-10 regulates movement of intestinally derived CD4+ T cells to the liver. J Immunol, 2007,178（12）：7974-7983.
[6] Gao B,Jeong WI,Tian Z,Liver：An organ with predominant innate immunity. Hepatology,2008,47（2）：729-736.
[7] Li L,Wu Z,Ma W,et al. Changes in intestinal microflora in patients with chronic severe hepatitis. Chin Med J,2001,114（8）：869-872.
[8] 吴仲文. 肠道屏障与肠道微生态. 中国危重病急救医学, 2004,16（12）：768-770.
[9] 鞠宝玲,唐小云,张红军,等. 菌群失调小鼠全身及肠道局部免疫功能的实验研究. 热带医学杂志,2008,8（5）：445-446.
[10] 杨洁,聂青和. 肝衰竭与肠道屏障功能障碍. 实用肝脏病杂志, 2010,13（1）：66-69.
[11] 朱宁川,陈岩. 肝病肠道菌群失调与肠源性内毒素血症. 中国微生态学杂志,2004,16（1）：61.
[12] Dagvadorj J,Tumurkhuu G,Naiki Y,et al. Endotoxin-induced lung injury in alpha-galactosylceramide-sensitized mice is caused by failure of interleukin-4 production in lung natural killer T cells. Clin Exp Immunol,2010,162（1）：169-177.
[13] 吴卫锋,戴玮玮. 细胞因子在慢性肝衰竭合并全身炎症反应综合征病例中的意义. 中国生化药物杂志,2009,30（1）：52-53.
[14] 江丰,吴蓉,吴小翎. 口服肠道益生菌制剂对肝硬化患者血浆脂多糖连接蛋白水平的影响及其临床意义. 实用肝脏病杂志,2006, 9（4）：246-248.
[15] Day CP,James OF. Steatohepatitis：a tale of two “hits”Gastroenterology,1998,114（4）：842-845.
[16] Farrell GC. Signalling links in the liver：knitting SOCS with fat and inflammation. J Hepatol,2005,43（1）：193-196.
[17] Vijay-Kumar M,Aitken JD,Carvalho FA,et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science,2010,328（5975）：228-231.
[18] Rabot S,Membrez M,Bruneau A,et al.Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. Faseb J,2010,24（12）：4948-4959.
[19] Abu-Shanab A,Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol, 2010,7（12）：691-701.
[20] Musso G,Gambino R,Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition：mechanisms and implications for metabolic disorders. Curr Opin Lipidol,2010, 21（1）：76-83.
[21] Musso G,Gambino R,Cassader M. Obesity,diabetes,and gut microbiota：the hygiene hypothesis expanded? Diabetes Care,2010,33（10）：2277-2284.
[22] Szabo G,Bala S,Petrasek J,et al. Gut-liver axis and sensing microbes. Dig Dis,2010,28（6）：737-744.
[23] Diamant M,Blaak EE,de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev,2011,2（4）：272-281.
[24] Iacono A,Raso GM,Canani RB,et al. Probiotics as an emerging therapeutic strategy to treat NAFLD：focus on molecular and biochemical mechanisms. J Nutr Biochem,2011,22（8）： 699-711.
[25] Sajjad A,Mottershead M,Syn WK,et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther,2005,22（4）：291-299.
[26] Fan JG,Xu ZJ,Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol, 2005,11（32）：5053-5056.
[27] Wu WC,Zhao W,Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol,2008,14（2）：313-317.
[28] Iacono A,Raso GM,Canani RB,et al. Probiotics as an emerging therapeutic strategy to treat NAFLD：focus on molecular and biochemical mechanisms. J Nutr Biochem,2011,22（8）：699-711.
[29] Cesaro C,Tiso A,Del Prete A,et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis,2011,43（6）：431-438.
[30] Rao RK,Seth A,Sheth P. Recent advances in alcoholic liver disease：Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol,2004,286（6）：G881-884.
[31] Szabo G,Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol,2010,16（11）：1321-1329.
[32] Mutlu E,Keshavarzian A,Engen P,et al. Intestinal dysbiosis： a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res,2009,33（10）：1836-1846.
[33] Bhonchal S,Nain CK,Taneja N,et al.Modification of small bowel microflora in chronic alcoholics with alcoholic liver disease. Trop Gastroenterol,2007,28（2）：64-66.
[34] Forsyth CB,Farhadi A,Jakate SM,et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol,2009,43（2）：163-172.
[35] Martin FP,Sprenger N,Yap IK,et al. Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res,2009,8（4）： 2090-2105.